Transdel Aims to Raise Its Profile

LA JOLLA, Calif.—Transdel Pharmaceuticals retained the Investor Relations Group (IRG) to serve as its investor relations and PR firm, with the goal of increasing awareness of Transdel’s proprietary transdermal delivery technology, Transdel™. While the company has focused traditionally on the drug delivery market, promoting its Ketotransdel™ cream formulation to deliver the NSAID ketoprofen, it is actively pursuing the application of the delivery technology for other pharma and cosmeceutical actives.